The Filgrastim Biosimilars Global Market Report 2020-30 by The Business Research Company describes and explains the global filgrastim biosimilars market and covers 2015 to 2020, termed the historic period, and 2020 to 2025, termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.
The Filgrastim Biosimilars Global Market Opportunities And Strategies Report covers filgrastim biosimilars market drivers, filgrastim biosimilars market trends, filgrastim biosimilars market segments, filgrastim biosimilars market growth rate, filgrastim biosimilars market major players, and filgrastim biosimilars market size.
View Complete Report:
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilars-market
The filgrastim biosimilars market report focuses particularly on identifying the trends, opportunities, and strategies that can lead to success. O&S reports are available off the shelf and can be delivered to clients on the day of purchase.
Filgrastim Biosimilars Global Market Opportunities And Strategies Report is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The chapter on the impact of COVID-19 gives valuable insights on supply chain disruptions, logistical challenges, and other economic implications of the virus on the market. The chapter also covers markets which have been positively affected by the pandemic.
Request For The Sample Now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3426&type=smp
Trends In The Market Include:
Shift Towards Development Of Biosimilars-
Pharmaceutical companies are shifting towards biosimilar drug development. Pharma companies had focused on small molecules for decades, but the rate of innovation in that field has slowed dramatically, leading to the shift towards biosimilars. These research and development (R&D) activities have led to increasing success rates in clinical trials for biosimilars. R&D is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the form of new and effective biosimilars. The unmet needs with respect to chronic disease therapies help pharmaceutical companies to innovate and develop biologic molecules. For instance, Amgen and Kirin Holdings Company are developing a filgrastim biosimilar which stimulates the growth of white blood cells to treat neutropenia, a common adverse event in patients receiving chemotherapy for breast cancer. Currently, the drug is in Phase I/II clinical study for breast cancer patients. In June 2020, Pfizer, an American multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its biosimilar drug for lowering the incidence of infection as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.
Demand For Biosimilars In The Treatment Of Neutropenia-
The demand for filgrastim biosimilars to treat chemotherapy-related neutropenia in cancer patients has been increasing owing to the cost effectiveness of the treatment and equivalent efficiency of the biosimilars to the long-used chemical and biological drugs. For instance, according to a comparative study conducted to understand the cost efficiency of filgrastim biosimilars, it was concluded that prophylaxis or treatment of febrile neutropenia with Zarzio is cost-efficient under all possible treatment scenarios relative to Neupogen and Neulasta. It was seen that the cost of Neupogen treatment ranged from $151 (1 day) to $2114 (14 days), compared to $112 and $1575 for Zarzio, thus yielding potential cost savings from $39 to $540 for the latter.
The market is segmented:
By Application –
a. Oncology
b. Chronic and Autoimmune Diseases
c. Blood disorders
d. Growth hormone deficiency
e. Others
By Distribution Channel –
a. Hospital pharmacies
b. Retail pharmacies
c. Online pharmacies
About The Business Research Company:
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. It has offices in the UK, the US and India and a network of trained researchers in 20+ countries globally.
Contact Information:
The Business Research Company
https://www.thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Blog: http://blog.tbrc.info/
